Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

**Body:**

The biopharmaceutical sector faced a sharp reality check this week after Novartis disclosed that its experimental cholesterol therapy failed to meet its primary endpoint in a late-stage trial. The drug was designed to lower lipoprotein(a), or Lp(a)—a genetically determined lipid particle linked to heart attacks and strokes. Unlike standard LDL cholesterol, Lp(a) levels are largely unaffected by diet or statins, making it a highly coveted target for drug developers.

Novartis was not alone in this bet. Several other drugmakers have invested heavily in Lp(a)-lowering candidates, hoping to replicate the success of earlier cardiovascular outcomes trials. The failure raises questions about whether reducing this specific lipid translates into meaningful clinical benefit, a hypothesis that now lacks pivotal support. Consequently, investors repriced risk across the broader biopharma complex, selling off shares of companies with similar pipelines.

**What to watch:** Upcoming data readouts from rival programs will be scrutinized for whether they can demonstrate efficacy where Novartis fell short. Additionally, regulators and clinicians will look for secondary analyses from the failed trial to see if any subgroup showed potential benefit. The episode underscores that biomarker reductions do not guarantee improved patient outcomes, a key distinction for those evaluating the sector’s long-term cardiovascular pipeline.